Eosinophilic Chronic Rhinosinusitis
Conditions
Interventions
None listed
Sponsors
Kawano Yoshiaki
Eligibility
Inclusion criteria
Inclusion criteria: 1. Provision of signed informed consent on the website 2. Aged >=18 years at the time of answering the web survey 3. History of ECRS diagnosis more than 3 months prior to the time of answering the web survey 4. The patients who have been receiving CRS related treatment 5. The patients who have been issued a beneficiary certificate for intractable ECRS
Exclusion criteria
Exclusion criteria: None.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of patient who are satisfied with current ECRS treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| 1: Mean SNOT-22 score (total and each subdomain score) -Proportion of patients with each category of SNOT-22 total score -Proportion of patients with each category of SNOT-22 subdomain score -Proportion of patients with each SNOT-22 cough score 2: Proportion of patients with not well-controlled asthma (ACT <20) 3: Proportion of patient who are satisfied with current ECRS treatment by biologics use/non biologics use -Mean SNOT-22 score (total and each subdomain score) by biologics use/non-biologics -Proportion of patients with each category of SNOT-22 total score by biologics use/non-biologics -Proportion of patients with each category of SNOT-22 subdomain score by biologics use/non-biologics -Proportion of patients with each SNOT-22 cough score by biologics use/non-biologics -Proportion of patients with not well-controlled asthma (ACT <20) by biologics use/non-biologics | — |
Contacts
Public ContactHitomi Uchimura
AstraZeneca K.K.
Outcome results
None listed